Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers
- 267 Downloads
Objectives and design
To date, no sufficiently sensitive and specific single marker has been found to predict the clinical course of sarcoidosis. We designed a cohort study to investigate whether a panel of biomarkers measured in bronchoalveolar lavage (BAL) and peripheral blood could help predict pulmonary function worsening during the clinical course of sarcoidosis.
We analyzed 30 individuals with histologically proven sarcoidosis. At baseline, participants underwent pulmonary function tests (PFTs), fiberoptic bronchoscopy and radiological investigations. BAL and blood cellular profiles were obtained from all individuals and six pro-inflammatory molecules were quantified in BAL and serum. PFTs were performed at follow-up visits over a 2-year period. Using discriminant function analysis, a canonical variable was generated to optimize the accuracy of selected variables in predicting pulmonary function worsening and was validated on a subset of nine consecutive individuals with sarcoidosis.
A combination of 6 markers from BAL was able to predict pulmonary function worsening in 96 % of patients [95 % confidence interval (CI) 84.4–99.81]. We validated the generated formula on a group of nine patients with sarcoidosis, obtaining 77.8 % correct classification (95 % CI 45.3–93.7).
Our results show that a combinational approach could contribute to identifying individuals likely to experience pulmonary function worsening, thus helping to decide the correct therapeutic strategies.
KeywordsBiomarker Discriminant analysis Disease severity Pulmonary function worsening Sarcoidosis
- 1.American Thoracic Society. Statement on sarcoidosis. Am J Respir Crit Care Med. 1999;160:736–55.Google Scholar
- 5.Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Bull Med. 1982;29:27–32.Google Scholar
- 12.Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML, British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee, Thoracic Society of Australia, New Zealand Thoracic Society, Irish Thoracic Society. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl 5):v1–58.PubMedGoogle Scholar
- 15.Hunninghake GW, Gilbert S, Pueringer R. Outcome of the treatment of sarcoidosis. Am J Respir Crit Care Med. 1994;49:893–8.Google Scholar
- 17.Overall JF, Kleitt JC. Use of canonical variate for classification. In: Applied multivariate analysis. New York: McGraw-Hill; 1978. p. 53–77.Google Scholar
- 27.Ameglio F, Giannarelli D, Cordiali-Fei P, Pietravalle M, Alemanno L, Paone G, Amicosante M, Saltini C, Bisetti A. Use of discriminant analysis to assess disease activity in pulmonary tuberculosis with a panel of specific and non-specific serum markers. Am J Clin Pathol. 1994;101:719–25.PubMedGoogle Scholar
- 29.Paone G, De Angelis G, Portalone L, Greco S, Giosué S, Taglienti A, Bisetti A, Ameglio F. Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors. Br J Cancer. 1997;75:448–50.PubMedCrossRefGoogle Scholar
- 44.Paone G, Di Tanna GL, Leone A, Batzella S, Conti V, Belli F, Galluccio G, Cammarella I, Sebastiani A, Terzano C, Vestri AR. Potential usefulness of a combination of inflammatory markers in identifying patients with sarcoidosis and monitoring respiratory functional worsening. Am J Clin Pathol. 2012;137:497–9.PubMedCrossRefGoogle Scholar